Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | IGF2R | P11717 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | GJA1 | P17302 | 1/20 | 0.44 |
| ▸ | GJB2 | P29033 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25551696 | 1.00 | MEN1 (0.50) | MEN1KMT2APTPN1L3MBTL1IGF2R | |
| SCHEMBL15844520 | 0.94 | MEN1 (0.42) | MEN1KMT2APTPN1L3MBTL1IGF2R | |
| SCHEMBL4277916 | 0.94 | MEN1 (0.42) | MEN1KMT2APTPN1L3MBTL1IGF2R | |
| SCHEMBL5357747 | 0.90 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL20111150 | 0.90 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL25304700 | 0.90 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| SCHEMBL17154856 | 0.90 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL19576005 | 0.90 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| SCHEMBL18197649 | 0.90 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA | |
| Trehalose SCHEMBL23029503 | 0.90 | MEN1 (0.57) | MEN1KMT2APTPN1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230046275-A1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR REDUCING OXIDATIVE DAMAGE TO AN EYE LENS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20210379200-A1 | USE OF CELL MEMBRANE-BOUND SIGNALING FACTORS | AIVITA BIOMEDICAL, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20200297855-A1 | STABLE, AQUEOUS FORMULATIONS OF ANTIBODIES THAT BIND IL5 RECEPTOR | MEDIMMUNE, LLC | 2020-09-24 | — | — | US | disclosed |
| US-10736909-B2 | Use of trehalose for treatment of neurological diseases | JUNAXO, INC. (CA) | 2020-08-11 | — | — | US | disclosed |
| US-20190046549-A1 | USE OF TREHALOSE FOR TREATMENT OF NEUROLOGICAL DISEASES | JUNAXO, INC. (CA) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297855-A1 | STABLE, AQUEOUS FORMULATIONS OF ANTIBODIES THAT BIND IL5 RECEPTOR | IL5, IL15RA, IL15 | MEN1 3182/4885KMT2A 3141/4885PTPN1 885/4885 |
| US-20210379200-A1 | USE OF CELL MEMBRANE-BOUND SIGNALING FACTORS | CD74, SDCBP, EPCAM | MEN1 4468/4885KMT2A 4789/4885PTPN1 2429/4885 |
| US-20230046275-A1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR REDUCING OXIDATIVE DAMAGE TO AN EYE LENS | TREH, CRYAB, CRYAA | MEN1 3455/4885KMT2A 4706/4885PTPN1 2182/4885 |
| US-20190046549-A1 | USE OF TREHALOSE FOR TREATMENT OF NEUROLOGICAL DISEASES | TREH, GALC, GBA2 | MEN1 2814/4885KMT2A 2302/4885PTPN1 971/4885 |
| US-10736909-B2 | Use of trehalose for treatment of neurological diseases | TREH, GALC, GBA2 | MEN1 2814/4885KMT2A 2302/4885PTPN1 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.